Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
Authors:
- Charles SwantonCSCharles Swanton
- James M LarkinJLJames M Larkin
- Marco GerlingerMGMarco Gerlinger
- Aron C EklundAEAron C Eklund
- Michael HowellMHMichael Howell
- Gordon StampGSGordon Stamp
- Julian DownwardJDJulian Downward
- Martin GoreMGMartin Gore
- P Andrew FutrealPFP Andrew Futreal
- Bernard EscudierBEBernard Escudier
- Fabrice AndreFAFabrice Andre
- Laurence AlbigesLALaurence Albiges
Open Access
- 11 August 2010
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 2 (8) , 1-10
Abstract
The European Union multi-disciplinary Personalised RNA interference to Enhance the Delivery of Individualised Cytotoxic and Targeted therapeutics (PREDICT) consortium has recently initiated a framework to accelerate the development of predictive biomarkers of individual patient response to anti-cancer agents. The consortium focuses on the identification of reliable predictive biomarkers to approved agents with anti-angiogenic activity for which no reliable predictive biomarkers exist: sunitinib, a multi-targeted tyrosine kinase inhibitor and everolimus, a mammalian target of rapamycin (mTOR) pathway inhibitor. Through the analysis of tumor tissue derived from pre-operative renal cell carcinoma (RCC) clinical trials, the PREDICT consortium will use established and novel methods to integrate comprehensive tumor-derived genomic data with personalized tumor-derived small hairpin RNA and high-throughput small interfering RNA screens to identify and validate functionally important genomic or transcriptomic predictive biomarkers of individual drug response in patients. PREDICT's approach to predictive biomarker discovery differs from conventional associative learning approaches, which can be susceptible to the detection of chance associations that lead to overestimation of true clinical accuracy. These methods will identify molecular pathways important for survival and growth of RCC cells and particular targets suitable for therapeutic development. Importantly, our results may enable individualized treatment of RCC, reducing ineffective therapy in drug-resistant disease, leading to improved quality of life and higher cost efficiency, which in turn should broaden patient access to beneficial therapeutics, thereby enhancing clinical outcome and cancer survival. The consortium will also establish and consolidate a European network providing the technological and clinical platform for large-scale functional genomic biomarker discovery. Here we review our current understanding of molecular mechanisms driving resistance to anti-angiogenesis agents, the current limitations of laboratory and clinical trial strategies and how the PREDICT consortium will endeavor to identify a new generation of predictive biomarkers.Keywords
This publication has 55 references indexed in Scilit:
- Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancerNature Medicine, 2010
- Biomarkers of response and resistance to antiangiogenic therapyNature Reviews Clinical Oncology, 2009
- Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencingNature Biotechnology, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNature Genetics, 2006
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Thousands of samples are needed to generate a robust gene list for predicting outcome in cancerProceedings of the National Academy of Sciences, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005